Eliem Therapeutics Inc

NASDAQ ELYM

Data sourced from

and

Download Data

Eliem Therapeutics Inc Total Assets for the year ending December 31, 2023: USD 110.47 M

Eliem Therapeutics Inc Total Assets is USD 110.47 M for the year ending December 31, 2023, a -18.17% change year over year. Total Assets is the total value of all assets owned by a company, representing its resources.

Eliem Therapeutics Inc Total Assets for the year ending December 31, 2022 was USD 134.99 M, a -22.08% change year over year.
Eliem Therapeutics Inc Total Assets for the year ending December 31, 2021 was USD 173.24 M, a 603.35% change year over year.
Eliem Therapeutics Inc Total Assets for the year ending December 31, 2020 was USD 24.63 M, a 15.13% change year over year.
Eliem Therapeutics Inc Total Assets for the year ending December 31, 2019 was USD 21.39 M.

NASDAQ: ELYM

Eliem Therapeutics Inc

CEO	Mr. Robert W. Azelby M.B.A.
IPO Date	Aug. 10, 2021
Location	United States
Headquarters	23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees	9
Sector	Healthcare
Industry	Biotechnology

Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Key trends